E
Enterprise Therapeutics
Novel muco-regulatory therapies for respiratory diseases
About Enterprise Therapeutics
Enterprise Therapeutics is a clinical-stage biopharmaceutical company founded in 2014, dedicated to developing treatments for respiratory diseases with high unmet medical needs. The company was co-founded by Professor Martin Gosling from the University of Sussex, who also serves as the Chief Scientific Officer. Enterprise Therapeutics is headquartered in Brighton, UK, with offices at the Sussex Innovation Centre and in London.
The company's primary focus is on discovering and developing disease-modifying therapies that address the underlying mechanisms of mucus congestion in conditions like cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and severe asthma. By targeting specific ion channels, these therapies aim to hydrate and clear mucus from the airways, which can reduce lung infections, restore lung function, and improve patients' quality of life. The business model centers on the research and development of a proprietary drug pipeline. The company has received significant backing from venture capital investors including Novartis Venture Fund, Versant Ventures, Forbion, and Panakes Partners.
A significant milestone was the acquisition of its TMEM16A potentiator portfolio, including the clinical-stage compound ETD002, by Roche in October 2020 for an upfront payment of £75 million. The company's lead program, ETD001, is a novel ENaC ion channel blocker designed for durable target engagement. In January 2024, Enterprise secured £26 million in a Series B follow-on financing to fund a Phase 2a clinical trial for ETD001 in cystic fibrosis patients who are ineligible for or not receiving CFTR modulators. The company also established an Italian subsidiary to expand its R&D and clinical activities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Lewes, United Kingdom
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Respiratory, Health Diagnostics, Spinout, Disease, Biotech and Pharma, DT and LS, uk is8 life sciences, UKSU, UKSU2010
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2024 | $26M | $145M | IP Group · Epidarex Capital · Panakès Partners · Forbion Capital Partners | ↗ |
| GRANTOther financing | Oct 2019 | $7.3M | — | Cystic Fibrosis Foundation | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Enterprise Therapeutics is 530 monthly website visits, down 42.4% over the last three months. Enterprise Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Enterprise Therapeutics in the Lewes ecosystem
The Enterprise Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cystic Fibrosis Foundation
Series A7 investors entered at this stage
Epidarex Capital
Imperial Innovations
Versant Ventures
Novartis Venture Fund
Forbion Capital Partners
IP Group
Panakès Partners
Other known investors2 additional known investors
Esher Sixth Form College
University of Aberdeen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enterprise Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enterprise Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









